MedTrace Logo

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

NCT04893148 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-07-20

No results posted yet for this study

Summary

The investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus dulaglutide as intensification from basal insulin with metformin, in the absence of head-to-head trials.

Conditions

Interventions

DRUG

IGlarLixi

Changing to iGlarLixi from insulin glargine

DRUG

Dulaglutide

Add dulaglutide to insulin glargine

Sponsors & Collaborators

  • Chungbuk National University Hospital

    lead OTHER

Principal Investigators

  • Eu Jeong Ku, MD, PhD · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2021-12-30
Completion
2022-12-30

Countries

  • South Korea

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893148 on ClinicalTrials.gov